Otic progenitor cell surface markers
AssigneeWDI 2 ApS
InventorsCharlotte Amalie NAVNTOFT, Juan Carlos Vilaescusa RAMIREZ, Carla AZEVEDO, Simone Møller JENSEN, Kan KANEKO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a cell population of spiral ganglion neural progenitors (SGNPs) and methods how to isolate these cells from an in-vitro mixed cell population. The cell population expresses one or more markers, wherein the one or more marker is CXCR4, SUSD2, LPAR3, EPHA5, CHRNA3, REEP1, NPFFR2, SORCS3, NFASC, GABRB3, KCNB2, GRM8, DLL3, and/or KCNH8.
Claims20
An in-vitro cell population comprising spiral ganglion neural progenitors (SGNPs), wherein said population expresses one or more markers, wherein the one or more marker is CXCR4, SUSD2, LPAR3, EPHA5, CHRNA3, REEP1, NPFFR2, SORCS3, NFASC, GABRB3, KCNB2, GRM8, DLL3, and/or KCNH8.
A method to identify spiral ganglion neural progenitors (SGNPs) from an in-vitro mixed cell population, the method comprising the step of:
- a. Detecting expression of at least one marker of, CXCR4,SUSD2, LPAR3, EPHA5, CHRNA3, REEP1, NPFFR2, SORCS3 NFASC, GABRB3, KCNB2, GRM8, DLL3 and KCNH8 on single cells of the in-vitro mixed cell population;
- thereby identifying a population comprising SGNPs from the in-vitro mixed population.
A method to isolate spiral ganglion neural progenitors (SGNPs) from an in-vitro mixed cell population, the method comprising the steps of:
- a. Detecting expression of at least one marker of CXCR4, SUSD2, LPAR3, EPHA5, CHRNA3, REEP1, NPFFR2, SORCS3, NFASC, GABRB3, KCNB2, GRM8, DLL3 and KCNH8 on single cells of the in-vitro mixed cell population;
- and
- b. Isolating the cells expressing at least one of the markers;
- thereby isolating a population comprising SGNPs from the in-vitro mixed population.
A method to enrich spiral ganglion neural progenitors (SGNPs) from an in-vitro mixed cell population, the method comprising the steps of:
- a. Detecting expression of at least one marker of CXCR4, SUSD2, LPAR3, EPHA5, CHRNA3, REEP1, NPFFR2, SORCS3, NFASC, GABRB3, KCNB2, GRM8, DLL3 and KCNH8 on single cells of the in-vitro mixed cell population;
- and
- b. Isolating the cells expressing at least one of the markers;
- thereby enriching a population of SGNPs from the in-vitro mixed population.
An in-vitro cell population comprising spiral ganglion neural progenitors (SGNPs) obtained by the method comprising following steps:
- a. Plating human pluripotent stem cells;
- b. Culturing the pluripotent stem cells in medium;
- c. Differentiating of the pluripotent stem cells in medium promoting the differentiation to otic progenitor cells;
- d. Differentiating the cells of step c) in medium activating BMP signaling;
- e Culturing the cells of step d) in medium comprising a BMP signal inhibitor and bFGF;
- and
- f. Proliferating the cells of step e) to obtain SGNPs;
- g. isolating cells from the population of step f) that exhibit one or more marker is CXCR4, SUSD2, LPAR3, EPHA5, CHRNA3, REEP1, NPFFR2, SORCS3, CXCR4, NFASC, GABRB3, KCNB2, GRM8, DLL3, and/or KCNH8.
Dependencies are inferred from the claim text.